论文信息 - Cost implications of the use of basal insulin glargine in people with early dysglycemia: the ORIGIN trial. - 字舞流文

Cost implications of the use of basal insulin glargine in people with early dysglycemia: the ORIGIN trial.

S. Yusuf | Hyejung Jung | A. Gafni | H. Gerstein | Kavita Singh | A. Lamy | J. Tyrwhitt | W. Tong | K. Singh | H. Jung

[1] Salim Yusuf,et al. Basal insulin and cardiovascular and other outcomes in dysglycemia. , 2012, The New England journal of medicine.

[2] S. Yusuf,et al. The cost of clopidogrel use in atrial fibrillation in the ACTIVE-A trial. , 2012, The Canadian journal of cardiology.

[3] S. Yusuf,et al. The cost implications of the use of telmisartan or ramipril in patients at high risk for vascular events: the ONTARGET study , 2011, Journal of medical economics.

[4] H. Gerstein,et al. Rationale, design, and baseline characteristics for a large international trial of cardiovascular disease prevention in people with dysglycemia: the ORIGIN Trial (Outcome Reduction with an Initial Glargine Intervention). , 2008, American heart journal.

[5] L. Mortensen,et al. Rationale , design , and baseline characteristics for a large international trial of cardiovascular disease prevention in people with dysglycemia : The ORIGIN Trial ( Outcome Reduction with an Initial Glargine Intervention ) , 2007 .

[6] J Carpenter,et al. Bootstrap confidence intervals: when, which, what? A practical guide for medical statisticians. , 2000, Statistics in medicine.

[7] A Briggs,et al. The Distribution of Health Care Costs and Their Statistical Analysis for Economic Evaluation , 1998, Journal of health services research & policy.

[8] M. Mcgrath. Cost Effectiveness in Health and Medicine. , 1998 .

[9] M. Gold. Cost-effectiveness in health and medicine , 2016 .